title: Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer.
abstract: OBJECTIVE
  Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) has recently been implicated in cancer development and progression. This study was performed to assess whether CEACAM-1 expression in primary tumors is correlated to long-term survival in patients with operable non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Primary tumors of 145 consecutive patients with completely resected NSCLC (pT(1-4) pN(0-2) M(0) R(0)) were stained immunohistochemically using the monoclonal anti-CEACAM-1 antibody 4D1/C2. The prognostic relevance of CEACAM-1 expression was evaluated by univariate Kaplan-Meier and multivariate Cox regression analysis. The median follow-up period was 72 months (range, 10-130 months).
  
  
  RESULTS
  Normal bronchiolar epithelium present in all sections exhibited no immunostaining. In contrast, 73 tumors (50.4%) showed between 1 and 66% CEACAM-1 positive tumor cells, and 72 tumors (49.6%) exhibited even a higher percentage of positive tumor cells. A high CEACAM-1 expression rate (i.e., >/=66% positive tumor cells) was more frequent in adenocarcinomas than in squamous cell carcinomas (61.9 versus 35.7%, respectively). Multivariate Cox regression analysis demonstrated that CEACAM-1 represents an independent prognosticator for cancer-related survival (P = 0.018; relative risk, 1.8; 95% confidence interval, 1.1-2.8). Subgroup analysis revealed that a high CEACAM-1 expression rate was of significant prognostic impact in pN(1)-pN(2) patients (n = 60; P = 0.024), pT(3)-pT(4) patients (n = 22; P = 0.009), and stage IIa-IIIa patients (n = 69; P = 0.012).
  
  
  CONCLUSIONS
  The absence of CEACAM-1 in normal lung tissue and its expression in tumor cells argues against a tumor-suppressive role of CEACAM-1 in NSCLC. The correlation between elevated CEACAM-1 expression and an unfavorable prognosis indicates rather that CEACAM-1 might promote lung cancer progression.
authors.affiliation: Department of Surgery, Chirurgische Klinik-Innenstadt, University of Munich, 80336 Munich, Germany. wulf.sienel@ch-i.med.uni-muenchen.de
authors.forename: Wulf
authors.initials: W
authors.lastname: Sienel
authors.forename: Sebastian
authors.initials: S
authors.lastname: Dango
authors.forename: Ute
authors.initials: U
authors.lastname: Woelfle
authors.forename: Alicia
authors.initials: A
authors.lastname: Morresi-Hauf
authors.forename: Christoph
authors.initials: C
authors.lastname: Wagener
authors.forename: Jens
authors.initials: J
authors.lastname: Brümmer
authors.forename: Wolf
authors.initials: W
authors.lastname: Mutschler
authors.forename: Bernward
authors.initials: B
authors.lastname: Passlick
authors.forename: Klaus
authors.initials: K
authors.lastname: Pantel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000032:analysis* / Q000502:physiology; D000943:Antigens, Differentiation / Q000032:analysis* / Q000502:physiology; D002289:Carcinoma, Non-Small-Cell Lung / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D015815:Cell Adhesion Molecules; D018450:Disease Progression; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D008875:Middle Aged
chemical_list: D015703:Antigens, CD; D000943:Antigens, Differentiation; C069847:CD66 antigens; D015815:Cell Adhesion Molecules